T-Cell Lymphoma Relapsed
3 clinical trials · Condition
◉ Watch T-Cell Lymphoma Relapsed
| Record | Firm | Date |
|---|---|---|
| Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma (NCT03552692) | Fondazione Italiana Linfomi - ETS | 2018-09-25 |
| Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma (NCT03046953) | University of Birmingham | 2017-12-08 |
| Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) (NCT02689453) | National Cancer Institute (NCI) | 2017-01-19 |
Track T-Cell Lymphoma Relapsed automatically
Every clearance here is in the API, with alerts when new ones post.